Skip to main content

Table 3 Mean cost (in euros) and mean effectiveness (in QALY) per patient for each maintenance strategy, during the different management periods after induction chemotherapy

From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

  Observation (n = 155) Gemcitabine (n = 154) Erlotinib (n = 155)
Parameter Cost QALY Cost QALY Cost QALY
Maintenance €702 0.202 €8,487 0.256 €10,551 0.241
Second-line €7,449 0.114 €6,412 0.103 €6,637 0.103
Palliative care €14,582 0.229 €13,497 0.260 €14,741 0.251
Total €22,734 0.545 €28,397 0.619 €31,928 0.595
Difference from observation €5,663 0.074 €9,195 0.050
ICER 76,625 [44,212 – 188,887] 184,733 [94,559 – 1,186,736]
  1. Legend: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.